Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 531 versus standard of care in non-splenectomized adults with chronic immune thrombocytopenic purpura
2006-003700-18Phase 3Completed
- Sponsor
- Amgen
- Start
- Dec 2006
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in immune thrombocytopenia (ITP) comparing Romiplostim with Medical standard of care (2 arms). Primary endpoints: Number of subjects undergoing splenectomy and Number of subjects with treatment failure. Started Dec 2006; status: completed.
02
Drugs
romiplostim
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on 2006-003700-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003700-18.